On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the day at $98.42. Traded volume was 10.31million shares in the last session and the average volume of the stock remained 8.80million shares. The beta of the stock remained 0.52. Johnson & Johnson (NYSE:JNJ) insider ownership is 0.02%.

Merck & Co. Inc (NYSE:MRK) Insider Bruce N. Kuhlik sold 145,225 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $56.43, for a total value of $8,195,046.75. Merck & Co., Inc. (NYSE:MRK) dropped -0.16 percent to $56.12 Friday on volume of 10.41million shares. The intra-day range of the stock was $56.09 to $56.72. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $165.03billion.

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer Inc. (NYSE:PFE)’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 – 25 years of age. Pfizer Inc. (NYSE:PFE)’s stock on Apr 04, 2014 reported a decrease of -0.74% to the closing price of $32.16. Its fifty two weeks range is $27.12-$32.96. The total market capitalization recorded $205.62billion. The overall volume in the last trading session was 26.28million shares. In its share capital, PFE has 6.39billion outstanding shares.

Mannkind Corporation (NASDAQ:MNKD) ripped higher this week after the company announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. On Friday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -0.87% to close the day at $6.87. Company monthly performance is recorded as 20.32%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 27.22%.